Contineum Therapeutics, Inc.

CTNM

Healthcare|Biotechnology|US

$9.52

+0.71 (+8.06%)

DCF Value

$2.40

Tangible Book / Share

$6.39

Cash / Share

$6.37

Clinical Trials (7)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07284459 Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	P2	Recruiting	324	RCT, Double-blind	PIPE-791 Dose A, PIPE-791 Dose B, Placebo
NCT04462198 Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss	Sensorineural Hearing Loss	P1P2	Completed	28	RCT, Double-blind	PIPE-505, Placebo
NCT04725175 Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers	Multiple Sclerosis	P1	Completed	70	RCT, Double-blind	PIPE-307, Placebo oral tablet
NCT06810245 Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain	Chronic Osteoarthritis Pain, Chronic Low Back Pain	P1	Completed	43	RCT, Double-blind	PIPE-791, Placebo
NCT06683612 PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF	Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis	P1	Completed	16	Open-label	PIPE-791
NCT05983939 Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers	Multiple Sclerosis	P1	Completed	56	RCT, Double-blind	PIPE-791, Placebo
NCT04941781 PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers	Multiple Sclerosis	P1	Completed	6	Open-label	PIPE-307